4 December 2014
No added benefit can be derived from the indirect comparison presented in the drug manufacturer dossier, in particular because the studies on the appropriate comparator therapy were unsuitable, scientists say.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/yubAHlyloUs/141204103127.htm
